Loading
A phase 2 trial of Osimertinib in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) is a phase 2 interventional study registered as NCT05526755 by AstraZeneca, with 188 participants enrolled, started 2023-03-06 and due to reach its primary completion in 2029-11-22. Interventions recorded: Osimertinib 80 mg/40 mg.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/